Impact of statin use on cancer recurrence and mortality in breast cancer: A systematic review and meta-analysis

International Journal of Cancer

Volumn 139, Issue 6, 2016, Pages 1281-1288

  Manthravadi, Sashidhar ^a   Shrestha, Anuj ^b   Madhusudhana, Sheshadri ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

adjuvant; breast cancer; lipid lowering medications; meta analysis; statin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; DRUG USE; FOLLOW UP; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 84977533199     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30185     Document Type: Review

References (33)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians 2015;65:5–29.
2. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2003;9:10–9.
3. Ling Y, Yang L, Huang H, et al. Prognostic significance of statin use in colorectal cancer: a systematic review and meta-analysis. Medicine 2015;94:e908.
4. Park HS, Schoenfeld JD, Mailhot RB, et al. Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2013;24:1427–34.
5. Ahern TP, Lash TL, Damkier P, et al. Statins and breast cancer prognosis: evidence and opportunities. The Lancet Oncology 2014;15:e461–e468.
6. Bjarnadottir O, Romero Q, Bendahl PO, et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Research and Treatment 2013;138:499–508.
7. Borgquist S, Jogi A, Ponten F, et al. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. Breast Cancer Research: BCR 2008;10:R79.
8. Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from wwwcochrane-handbookorg.
9. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–12.
10. Rothman KJ, Greenland S, Lash TL. Modern epidemiologyed: Lippincott Williams & Wilkins, 2008.
11. Wells G, Shea B, O'connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, 2000.
12. Ahern TP, Pedersen L, Tarp M, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. Journal of the National Cancer Institute 2011;103:1461–8.
13. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Independent Subgroups within a Study Introduction to Meta-Analysed: John Wiley & Sons, Ltd, 2009: 217–23.
14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539–58.
15. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence—inconsistency. Journal of Clinical Epidemiology 2011;64:1294–302.
16. Review Manager (RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
17. Desai P, Lehman A, Chlebowski RT, et al. Statins and breast cancer stage and mortality in the Women's Health Initiative. Cancer Causes & Control: CCC 2015;26:529–39.
18. Cardwell CR, Hicks BM, Hughes C, et al. Statin use after diagnosis of breast cancer and survival: a population-based cohort study. Epidemiology (Cambridge, Mass) 2015;26:68–78.
19. Murtola TJ, Visvanathan K, Artama M, et al. Statin use and breast cancer survival: a nationwide cohort study from Finland. PloS One 2014;9:e110231.
20. Boudreau DM, Yu O, Chubak J, et al. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Research and Treatment 2014;144:405–16.
21. Zeichner SB, Shah NN, Montero AJ, et al. Improved clinical outcomes associated with statin use during adjuvant chemotherapy in patients with HER2+ non-metastatic breast cancer. Cancer Research 2013;73.
22. Nickels S, Vrieling A, Seibold P, et al. Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohort. PloS One 2013;8:e75088.
23. Brewer TM, Masuda H, Liu DD, et al. Statin use in primary inflammatory breast cancer: a cohort study. British Journal of Cancer 2013;109:318–24.
24. Botteri E, Munzone E, Rotmensz N, et al. Therapeutic effect of beta-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Research and Treatment 2013;140:567–75.
25. Chae YK, Valsecchi ME, Kim J, et al. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Investigation 2011;29:585–93.
26. Ceacareanu AC, Hong C, Brennan JJ, Epstein M, Kossoff E, Nimako GK, Patel K, Forrest A. Statin treatment use in diabetic patients with breast cancer: A potential C-reactive protein mediated benefit. Journal of Clinical Oncology 2011;29.
27. Kwan ML, Habel LA, Flick ED, et al. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Research and Treatment 2008;109:573–9.
28. Chavez-Mac Gregor M, Lei X, Litton JK, et al. Statin use and outcome among breast cancer patients treated with neoadjuvant systemic chemotherapy. Cancer Research 2013;73.
29. Sendur MA, Aksoy S, Yazici O, et al. Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer. Medical Oncology 2014;31:835.
30. Cheng L, Swartz MD, Zhao H, et al. Hazard of recurrence among women after primary breast cancer treatment–a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2012;21:800–9.
31. Sullivan KM, Foster DA. Use of the confidence interval function. Epidemiology 1990; 39–42.
32. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2012;23: vi7–12.
33. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. American Journal of Epidemiology 2007;166:348–54.